Perfil dos custos ambulatoriais no tratamento de neoplasia prostática
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora (UFJF)
Abstract
Prostate cancer (CaP) is the most common cancer among men and the second type
that most progresses to death in these patients. Health expenditures can represent an
important portion of government investments, especially in countries where the health
system is universal. The research aimed to estimate the direct medical costs of
prostate cancer care in the outpatient setting of the Unified Health System, between
2009 and 2018. This is a descriptive, retrospective study, with a ten-year time horizon.
A partial economic analysis was carried out in order to verify the direct medical costs
in the treatment of prostate cancer in a pole city in the macro-southeast of Minas
Gerais. The selection of medical records was based on the International Code of
Diseases (ICD), the ICD-10, and the data through the Information Technology
Department of the Unified Health System (DATASUS). 94,001 procedures were
selected, from which they were performed in 2,303 patients during the study period,
with a mean of 38.7 ± 43.01 (mean ± standard deviation) procedures per patient. The
average age ranged from 60 to 97 years. In relation to ethnicity, 36.97% white, 9.74%
black, 6.05% brown, the distribution of assistance was 32.4% in ASCOMCER; 19.7%
at the Dr. João Felício Hospital and 47.8% at the Oncological Institute. 94001
procedures were paid by SUS at a total cost of R$35,858,257.15. The mean cost per
procedure was R$381.47 ± R$472.28 (mean ± standard deviation). The evidence
identified in this research can be used to inform the planning of clinical services,
budgets and contribute to the promotion of future research on health economic
evaluations.
Description
Keywords
Citation
Collections
Endorsement
Review
Supplemented By
Referenced By
Creative Commons license
Except where otherwise noted, this item's license is described as Acesso Aberto

